Holen Sie sich die Stockscreener-App
125.80
0.42%
0.91
Schlusskurs vom Vortag:
$124.89
Offen:
$124
24-Stunden-Volumen:
921.89K
Relative Volume:
0.28
Marktkapitalisierung:
$27.45B
Einnahmen:
$819.56M
Nettoeinkommen (Verlust:
$-1.18B
KGV:
-21.90
EPS:
-5.7434
Netto-Cashflow:
$-951.64M
1W Leistung:
-0.96%
1M Leistung:
-4.34%
6M Leistung:
-12.38%
1J Leistung:
-14.80%
1-Tages-Spanne:
$121.03
$128.97
1-Wochen-Bereich:
$121.03
$128.97
52-Wochen-Spanne:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
125.69 | 27.27B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
523.00 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
800.20 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,000.04 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.94 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.37 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-03-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Insmed rated Strong Buy with 39% upside on robu... - Pluang
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today - Benzinga
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
Insmed to Present Data across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - marketscreener.com
Insmed Grants Inducement Awards to 128 New Employees - Intellectia AI
128 new employees receive stock awards from Insmed - Stock Titan
INSM Looks 38.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Insmed presents new respiratory drug data at ER... - Pluang
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - PR Newswire
The top 12 companies hiring in biopharma now - BioSpace
Insmed director Sharoky sells $637,650 of Insmed stock By Investing.com - Investing.com Nigeria
Insmed director Sharoky sells $637,650 of Insmed stock - Investing.com
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges? - Yahoo Finance
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business - Yahoo Finance
Insmed Incorporated (INSM): Investor Outlook on a Biotech Pioneer with 68.87% Potential Upside - DirectorsTalk Interviews
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now? - Zacks Investment Research
Insmed will speak at two New York healthcare conferences in September - Stock Titan
Insmed to Present at September 2026 Investor Conferences - PR Newswire
Insmed director Melvin Sharoky sells $637,650 in shares - Investing.com
Mizuho raises Insmed stock price target to $195 on Japan approval - Investing.com
Insmed (INSM) Q2 2026 Earnings Call Transcript - AOL.com
Biotech Is Booming, But These 2 Stocks Missed the Memo - Sahm
Insmed Slides 4.3% as Recent Insider Sales and Post-Earnings Profit-Taking Weigh on Shares - Quiver Quantitative
Insmed Director Melvin Sharoky Reports Sale of 5,000 Shares via Padonia, LLC - Kalkine Media
Insmed Insider Sold Shares Worth $637,650, According to a Recent SEC Filing - marketscreener.com
Insmed (NASDAQ: INSM) director sells 5,000 shares via Padonia LLC - Stock Titan
How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story - simplywall.st
BMO Capital Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $192 - Moomoo
Insmed (NASDAQ: INSM) holder Padonia targets $638K share sale - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Insmed CMO Martina Flammer sells $3.49m in company stock By Investing.com - Investing.com Australia
Insmed CMO Martina Flammer sells $3.49m in company stock - Investing.com
H.C. Wainwright Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $220 - Moomoo
13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc. - MarketBeat
Insmed, Inc. $INSM Shares Bought by Empowered Funds LLC - MarketBeat
Darwin Global updates Insmed Inc (INSM) ownership, reporting 3.0% beneficial stake - Stock Titan
Insmed(INSM.US) Officer Sells US$31.96 Million in Common Stock - moomoo.com
FY2026 Earnings Forecast for Insmed Issued By HC Wainwright - MarketBeat
Handelsbanken Fonder AB Grows Stake in Insmed, Inc. $INSM - MarketBeat
Insmed (NASDAQ:INSM) COO Sells 239,850 Shares - MarketBeat
Insmed Insider Sold Shares Worth $31,964,810, According to a Recent SEC Filing - marketscreener.com
Insmed Chief Operating Officer Sold Shares Worth Over $31M - TradingView
INSMED Inc (INSM) COO exercises 239,850 options and sells matching shares - Stock Titan
HC Wainwright Brokers Increase Earnings Estimates for Insmed - MarketBeat
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 - kalkine.ca
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
INSM (INSM) insider notice covers 239,850 shares and prior sales data - Stock Titan
INSM Maintained by JP Morgan -- Price Target Lowered to $175 - GuruFocus
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):